<!DOCTYPE html>
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>References | Group Sequential Design Under Non-Proportional Hazards</title>
<meta name="author" content="Keaven M. Anderson, Yilong Zhang, Nan Xiao, and Yujie Zhao">
<meta name="description" content="[1] Miettinen, T. A., Pyörälä, K., Olsson, A. G., Musliner, T. A., Cook, T. J., Faergeman, O., Berg, K., Pedersen, T., Kjekshus, J. and Group, for the S. S. S. (1997). Cholesterol-lowering...">
<meta name="generator" content="bookdown 0.34 with bs4_book()">
<meta property="og:title" content="References | Group Sequential Design Under Non-Proportional Hazards">
<meta property="og:type" content="book">
<meta property="og:description" content="[1] Miettinen, T. A., Pyörälä, K., Olsson, A. G., Musliner, T. A., Cook, T. J., Faergeman, O., Berg, K., Pedersen, T., Kjekshus, J. and Group, for the S. S. S. (1997). Cholesterol-lowering...">
<meta name="twitter:card" content="summary">
<meta name="twitter:title" content="References | Group Sequential Design Under Non-Proportional Hazards">
<meta name="twitter:description" content="[1] Miettinen, T. A., Pyörälä, K., Olsson, A. G., Musliner, T. A., Cook, T. J., Faergeman, O., Berg, K., Pedersen, T., Kjekshus, J. and Group, for the S. S. S. (1997). Cholesterol-lowering...">
<!-- JS --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://kit.fontawesome.com/6ecbd6c532.js" crossorigin="anonymous"></script><script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="libs/bootstrap-4.6.0/bootstrap.min.css" rel="stylesheet">
<script src="libs/bootstrap-4.6.0/bootstrap.bundle.min.js"></script><script src="libs/bs3compat-0.5.0/transition.js"></script><script src="libs/bs3compat-0.5.0/tabs.js"></script><script src="libs/bs3compat-0.5.0/bs3compat.js"></script><link href="libs/bs4_book-1.0.0/bs4_book.css" rel="stylesheet">
<script src="libs/bs4_book-1.0.0/bs4_book.js"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- CSS --><style type="text/css">
    
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  </style>
<style type="text/css">
    /* Used with Pandoc 2.11+ new --citeproc when CSL is used */
    div.csl-bib-body { }
    div.csl-entry {
      clear: both;
        }
    .hanging div.csl-entry {
      margin-left:2em;
      text-indent:-2em;
    }
    div.csl-left-margin {
      min-width:2em;
      float:left;
    }
    div.csl-right-inline {
      margin-left:2em;
      padding-left:1em;
    }
    div.csl-indent {
      margin-left: 2em;
    }
  </style>
<link rel="stylesheet" href="style.css">
</head>
<body data-spy="scroll" data-target="#toc">

<div class="container-fluid">
<div class="row">
  <header class="col-sm-12 col-lg-3 sidebar sidebar-book"><a class="sr-only sr-only-focusable" href="#content">Skip to main content</a>

    <div class="d-flex align-items-start justify-content-between">
      <h1>
        <a href="index.html" title="Deming Conference Course, December 6, 2021">Group Sequential Design Under Non-Proportional Hazards</a>:
        <small class="text-muted">Deming Conference Course, December 6, 2021</small>
      </h1>
      <button class="btn btn-outline-primary d-lg-none ml-2 mt-1" type="button" data-toggle="collapse" data-target="#main-nav" aria-expanded="true" aria-controls="main-nav"><i class="fas fa-bars"></i><span class="sr-only">Show table of contents</span></button>
    </div>

    <div id="main-nav" class="collapse-lg">
      <form role="search">
        <input id="search" class="form-control" type="search" placeholder="Search" aria-label="Search">
</form>

      <nav aria-label="Table of contents"><h2>Table of contents</h2>
        <ul class="book-toc list-unstyled">
<li><a class="" href="index.html">Welcome!</a></li>
<li><a class="" href="preface.html">Preface</a></li>
<li><a class="" href="background.html"><span class="header-section-number">1</span> Background</a></li>
<li><a class="" href="proportional-hazards.html"><span class="header-section-number">2</span> Proportional hazards</a></li>
<li><a class="" href="ahr.html"><span class="header-section-number">3</span> Average hazard ratio</a></li>
<li><a class="" href="pkgs.html"><span class="header-section-number">4</span> Introduction to gsdmvn, gsDesign2, and simtrial</a></li>
<li class="book-part">Others tests</li>
<li><a class="" href="overview-other-tests.html"><span class="header-section-number">5</span> Overview</a></li>
<li><a class="" href="fixed-design.html"><span class="header-section-number">6</span> Fixed design</a></li>
<li><a class="" href="wlr.html"><span class="header-section-number">7</span> Weighted logrank test</a></li>
<li><a class="" href="wlr-boundary.html"><span class="header-section-number">8</span> Group sequential design boundary with weighted logrank test</a></li>
<li><a class="" href="maxcombo.html"><span class="header-section-number">9</span> MaxCombo test</a></li>
<li><a class="" href="maxcombo-boundary.html"><span class="header-section-number">10</span> Group sequential design boundary with MaxCombo test</a></li>
<li><a class="active" href="references.html">References</a></li>
</ul>

        <div class="book-extra">
          <p><a id="book-repo" href="https://github.com/keaven/gsd-deming">View book source <i class="fab fa-github"></i></a></p>
        </div>
      </nav>
</div>
  </header><main class="col-sm-12 col-md-9 col-lg-7" id="content"><div id="references" class="section level1 unnumbered">
<h1>References<a class="anchor" aria-label="anchor" href="#references"><i class="fas fa-link"></i></a>
</h1>

<div id="refs" class="references csl-bib-body">
<div id="ref-simva4s" class="csl-entry">
<div class="csl-left-margin">[1] </div>
<div class="csl-right-inline">Miettinen, T. A., Pyörälä, K., Olsson, A. G., Musliner, T. A., Cook, T. J., Faergeman, O., Berg, K., Pedersen, T., Kjekshus, J. and Group, for the S. S. S. (1997). Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the scandinavian simvastatin survival study (4S). <em>Circulation</em> <strong>96</strong> 4211–8.</div>
</div>
<div id="ref-LanDeMets" class="csl-entry">
<div class="csl-left-margin">[2] </div>
<div class="csl-right-inline">Lan, K. K. G. and DeMets, D. L. (1983). Discrete sequential boundaries for clinical trials. <em>Biometrika</em> <strong>70</strong> 659–63.</div>
</div>
<div id="ref-haybittle1971repeated" class="csl-entry">
<div class="csl-left-margin">[3] </div>
<div class="csl-right-inline">Haybittle, J. (1971). Repeated assessment of results in clinical trials of cancer treatment. <em>The British Journal of Radiology</em> <strong>44</strong> 793–7.</div>
</div>
<div id="ref-wang1987approximately" class="csl-entry">
<div class="csl-left-margin">[4] </div>
<div class="csl-right-inline">Wang, S. K. and Tsiatis, A. A. (1987). Approximately optimal one-parameter boundaries for group sequential trials. <em>Biometrics</em> 193–9.</div>
</div>
<div id="ref-pocock1977group" class="csl-entry">
<div class="csl-left-margin">[5] </div>
<div class="csl-right-inline">Pocock, S. J. (1977). Group sequential methods in the design and analysis of clinical trials. <em>Biometrika</em> <strong>64</strong> 191–9.</div>
</div>
<div id="ref-o1979multiple" class="csl-entry">
<div class="csl-left-margin">[6] </div>
<div class="csl-right-inline">O’Brien, P. C. and Fleming, T. R. (1979). A multiple testing procedure for clinical trials. <em>Biometrics</em> 549–56.</div>
</div>
<div id="ref-JTBook" class="csl-entry">
<div class="csl-left-margin">[7] </div>
<div class="csl-right-inline">Jennison, C. and Turnbull, B. W. (2000). <em>Group sequential methods with applications to clinical trials</em>. Chapman; Hall/CRC, Boca Raton, FL.</div>
</div>
<div id="ref-KEYNOTE189" class="csl-entry">
<div class="csl-left-margin">[8] </div>
<div class="csl-right-inline">Gandhi, L., Rodrı́guez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018). Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. <em>New England Journal of Medicine</em> <strong>378</strong> 2078–92.</div>
</div>
<div id="ref-AFCAPSdesign" class="csl-entry">
<div class="csl-left-margin">[9] </div>
<div class="csl-right-inline">Downs, J. R., Beere, P. A., Whitney, E., Clearfield, M., Weis, S., Rochen, J., Stein, E. A., Shapiro, D. R., Langendorfer, A. and Gotto Jr, A. M. (1997). Design &amp; rationale of the air force/texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS). <em>The American Journal of Cardiology</em> <strong>80</strong> 287–93.</div>
</div>
<div id="ref-AFCAPSresults" class="csl-entry">
<div class="csl-left-margin">[10] </div>
<div class="csl-right-inline">Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto Jr, A. M., et al. (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. <em>Journal of the American Medical Association</em> <strong>279</strong> 1615–22.</div>
</div>
<div id="ref-EXAMINEresults" class="csl-entry">
<div class="csl-left-margin">[11] </div>
<div class="csl-right-inline">White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013). Alogliptin after acute coronary syndrome in patients with type 2 diabetes. <em>New England Journal of Medicine</em> <strong>369</strong> 1327–35.</div>
</div>
<div id="ref-LachinFoulkes" class="csl-entry">
<div class="csl-left-margin">[12] </div>
<div class="csl-right-inline">Lachin, J. M. and Foulkes, M. A. (1986a). Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. <em>Biometrics</em> <strong>42</strong> 507–19.</div>
</div>
<div id="ref-KimTsiatis" class="csl-entry">
<div class="csl-left-margin">[13] </div>
<div class="csl-right-inline">Kim, K. and Tsiatis, A. A. (1990). Study duration for clinical trials with survival response and early stopping rule. <em>Biometrics</em> <strong>46</strong> 81–92.</div>
</div>
<div id="ref-Schoenfeld1981" class="csl-entry">
<div class="csl-left-margin">[14] </div>
<div class="csl-right-inline">Schoenfeld, D. (1981). The asymptotic properties of nonparametric tests for comparing survival distributions. <em>Biometrika</em> <strong>68</strong> 316–9.</div>
</div>
<div id="ref-MaurerBretz2013" class="csl-entry">
<div class="csl-left-margin">[15] </div>
<div class="csl-right-inline">Maurer, W. and Bretz, F. (2013). <a href="https://doi.org/10.1080/19466315.2013.807748">Multiple testing in group sequential trials using graphical approaches</a>. <em>Statistics in Biopharmaceutical Research</em> <strong>5</strong> 311–20.</div>
</div>
<div id="ref-HSD" class="csl-entry">
<div class="csl-left-margin">[16] </div>
<div class="csl-right-inline">Hwang, I. K., Shih, W. J. and De Cani, J. S. (1990). Group sequential designs using a family of type i error probability spending functions. <em>Statistics in Medicine</em> <strong>9</strong> 1439–45.</div>
</div>
<div id="ref-EXAMINEdesign" class="csl-entry">
<div class="csl-left-margin">[17] </div>
<div class="csl-right-inline">White, W. B., Bakris, G. L., Bergenstal, R. M., Cannon, C. P., Cushman, W. C., Fleck, P., Heller, S., Mehta, C., Nissen, S. E., Perez, A., et al. (2011). EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): A cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. <em>American Heart Journal</em> <strong>162</strong> 620–6.</div>
</div>
<div id="ref-deCastroGAMLSS" class="csl-entry">
<div class="csl-left-margin">[18] </div>
<div class="csl-right-inline">De Castro, M., Cancho, V. G. and Rodrigues, J. (2010). A hands-on approach for fitting long-term survival models under the GAMLSS framework. <em>Computer Methods and Programs in Biomedicine</em> <strong>97</strong> 168–77.</div>
</div>
<div id="ref-Zhang2018" class="csl-entry">
<div class="csl-left-margin">[19] </div>
<div class="csl-right-inline">Zhang, Y. and Shao, Y. (2018). Concordance measure and discriminatory accuracy in transformation cure models. <em>Biostatistics</em> <strong>19</strong> 14–26.</div>
</div>
<div id="ref-Zeng2006" class="csl-entry">
<div class="csl-left-margin">[20] </div>
<div class="csl-right-inline">Zeng, D., Yin, G. and Ibrahim, J. G. (2006). Semiparametric transformation models for survival data with a cure fraction. <em>Journal of the American Statistical Association</em> <strong>101</strong> 670–84.</div>
</div>
<div id="ref-hellmann2017estimating" class="csl-entry">
<div class="csl-left-margin">[21] </div>
<div class="csl-right-inline">Hellmann, M. D., Ma, J., Garon, E. B., Hui, R., Gandhi, L., Soria, J.-C., Anderson, K. M., Lubiniecki, G. M., Piperdi, B. and Herbst, R. S. (2017). Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and-010.</div>
</div>
<div id="ref-LanDeMets1989" class="csl-entry">
<div class="csl-left-margin">[22] </div>
<div class="csl-right-inline">Lan, K. K. G. and DeMets, D. L. (1989). <a href="https://doi.org/10.1002/sim.4780081003">Group sequential procedures: Calendar versus information time</a>. <em>Statistics in Medicine</em> <strong>8</strong> 1191–8.</div>
</div>
<div id="ref-FHRhoGamma" class="csl-entry">
<div class="csl-left-margin">[23] </div>
<div class="csl-right-inline">Harrington, D. P. and Fleming, T. R. (1982). A class of rank test procedures for censored survival data. <em>Biometrika</em> <strong>69</strong> 553–66.</div>
</div>
<div id="ref-MagirrBurman" class="csl-entry">
<div class="csl-left-margin">[24] </div>
<div class="csl-right-inline">Magirr, D. and Burman, C.-F. (2019a). Modestly weighted logrank tests. <em>Statistics in Medicine</em> <strong>38</strong> 3782–90.</div>
</div>
<div id="ref-NPHWG2020sim" class="csl-entry">
<div class="csl-left-margin">[25] </div>
<div class="csl-right-inline">Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J., Liu, R., Luo, X., et al. (2020). Alternative analysis methods for time to event endpoints under nonproportional hazards: A comparative analysis. <em>Statistics in Biopharmaceutical Research</em> <strong>12</strong> 187–98.</div>
</div>
<div id="ref-NPHWG2021Design" class="csl-entry">
<div class="csl-left-margin">[26] </div>
<div class="csl-right-inline">Roychoudhury, S., Anderson, K. M., Ye, J. and Mukhopadhyay, P. (2021). Robust design and analysis of clinical trials with non-proportional hazards: A straw man guidance from a cross-pharma working group. <em>Statistics in Biopharmaceutical Research</em> 1–37.</div>
</div>
<div id="ref-yung2019sample" class="csl-entry">
<div class="csl-left-margin">[27] </div>
<div class="csl-right-inline">Yung, G. and Liu, Y. (2019). Sample size and power for the weighted log-rank test and kaplan-meier based tests with allowance for nonproportional hazards. <em>Biometrics</em>.</div>
</div>
<div id="ref-lachin1986evaluation" class="csl-entry">
<div class="csl-left-margin">[28] </div>
<div class="csl-right-inline">Lachin, J. M. and Foulkes, M. A. (1986b). Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. <em>Biometrics</em> 507–19.</div>
</div>
<div id="ref-magirr2019modestly" class="csl-entry">
<div class="csl-left-margin">[29] </div>
<div class="csl-right-inline">Magirr, D. and Burman, C.-F. (2019b). Modestly weighted logrank tests. <em>Statistics in Medicine</em> <strong>38</strong> 3782–90.</div>
</div>
<div id="ref-karrison2016versatile" class="csl-entry">
<div class="csl-left-margin">[30] </div>
<div class="csl-right-inline">Karrison, T. G. (2016). Versatile tests for comparing survival curves based on weighted log-rank statistics. <em>The Stata Journal</em> <strong>16</strong> 678–90.</div>
</div>
<div id="ref-wang2019simulation" class="csl-entry">
<div class="csl-left-margin">[31] </div>
<div class="csl-right-inline">Wang, L., Luo, X. and Zheng, C. (2019). A simulation-free group sequential design with max-combo tests in the presence of non-proportional hazards. <em>arXiv preprint arXiv:1911.05684</em>.</div>
</div>
<div id="ref-scharfstein1997semiparametric" class="csl-entry">
<div class="csl-left-margin">[32] </div>
<div class="csl-right-inline">Scharfstein, D. O., Tsiatis, A. A. and Robins, J. M. (1997). Semiparametric efficiency and its implication on the design and analysis of group-sequential studies. <em>Journal of the American Statistical Association</em> <strong>92</strong> 1342–50.</div>
</div>
<div id="ref-gordon1983discrete" class="csl-entry">
<div class="csl-left-margin">[33] </div>
<div class="csl-right-inline">Gordon Lan, K. and DeMets, D. L. (1983). Discrete sequential boundaries for clinical trials. <em>Biometrika</em> <strong>70</strong> 659–63.</div>
</div>
<div id="ref-lachin2005review" class="csl-entry">
<div class="csl-left-margin">[34] </div>
<div class="csl-right-inline">Lachin, J. M. (2005). A review of methods for futility stopping based on conditional power. <em>Statistics in Medicine</em> <strong>24</strong> 2747–64.</div>
</div>
</div>
</div>
  <div class="chapter-nav">
<div class="prev"><a href="maxcombo-boundary.html"><span class="header-section-number">10</span> Group sequential design boundary with MaxCombo test</a></div>
<div class="empty"></div>
</div></main><div class="col-md-3 col-lg-2 d-none d-md-block sidebar sidebar-chapter">
    <nav id="toc" data-toggle="toc" aria-label="On this page"><h2>On this page</h2>
      <ul class="nav navbar-nav"><li><a class="nav-link" href="#references">References</a></li></ul>

      <div class="book-extra">
        <ul class="list-unstyled">
<li><a id="book-source" href="https://github.com/keaven/gsd-deming/blob/master/references.Rmd">View source <i class="fab fa-github"></i></a></li>
          <li><a id="book-edit" href="https://github.com/keaven/gsd-deming/edit/master/references.Rmd">Edit this page <i class="fab fa-github"></i></a></li>
        </ul>
</div>
    </nav>
</div>

</div>
</div> <!-- .container -->

<footer class="bg-primary text-light mt-5"><div class="container"><div class="row">

  <div class="col-12 col-md-6 mt-3">
    <p>"<strong>Group Sequential Design Under Non-Proportional Hazards</strong>: Deming Conference Course, December 6, 2021" was written by Keaven M. Anderson, Yilong Zhang, Nan Xiao, and Yujie Zhao. It was last built on 2023-07-28.</p>
  </div>

  <div class="col-12 col-md-6 mt-3">
    <p>This book was built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package.</p>
  </div>

</div></div>
</footer><!-- dynamically load mathjax for compatibility with self-contained --><script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.9/latest.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script><script type="text/x-mathjax-config">const popovers = document.querySelectorAll('a.footnote-ref[data-toggle="popover"]');
for (let popover of popovers) {
  const div = document.createElement('div');
  div.setAttribute('style', 'position: absolute; top: 0, left:0; width:0, height:0, overflow: hidden; visibility: hidden;');
  div.innerHTML = popover.getAttribute('data-content');

  var has_math = div.querySelector("span.math");
  if (has_math) {
    document.body.appendChild(div);
    MathJax.Hub.Queue(["Typeset", MathJax.Hub, div]);
    MathJax.Hub.Queue(function() {
      popover.setAttribute('data-content', div.innerHTML);
      document.body.removeChild(div);
    })
  }
}
</script>
</body>
</html>
